Related Papers
Journal of Managed Care Pharmacy
Cost-effectiveness analysis of tildrakizumab in patients with moderate to severe plaque psoriasis in the United States
2018 •
Alan Mendelsohn
Cost-effectiveness and budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs
2019 •
Alan Mendelsohn
756 Association Between Cardiometabolic Risk Factors and Body Mass Index Based on Diagnosis and Treatment Codes in an Electronic Medical Record Database
2008 •
Shawn Burke
BACKGROUND: Managed care organizations (MCOs) have access to treatment and diagnosis information from administrative claims data but generally have limited or no access to clinical information about laboratory values or biometric values such as body mass index (BMI) or waist circum- ference. Thus, MCOs are generally unable to identify overweight patients with cardiometabolic risk factors that put them at a
352 Administrative Claims Analysis of All-Cause Annual Costs of Care and Resource Utilization by Age Category for Ulcerative Colitis Patients
2008 •
Boxiong Tang
BACKGROUND: Ulcerative colitis (UC) is a chronic inflammatory disease with peak incidence in the third decade of life and a second peak in the sixth or seventh decade. While drug therapy can be used to control the inflammation and reduce symptoms, patients with UC may be treated surgically. There is little information in the published literature evaluating the all-cause health
Journal of Managed Care Pharmacy Jmcp
Sensitivity of administrative claims to identify incident cases of lung cancer: a comparison of 3 health plans
2009 •
Carolina Reyes
43 Higher Costs and Therapeutic Factors Associated With Adherence to NCQA HEDIS Antidepressant Medication Management Measures: Analysis of Administrative Claims
2006 •
Joseph Johnston, Ralph Swindle
2-5 This study examines factors associated with adher- ence to national treatment guidelines, including investigations of the impact of antidepressant and initial dosage level on adherence measures and costs. An estimated 16% of the costs of antidepressant treatment were found to be associated with patients who were never adequately treated. 4 Inadequate dose and duration of anti- depressant treatment has
Journal of managed care & specialty pharmacy
Examination of the Link Between Medication Adherence and Use of Mail-Order Pharmacies in Chronic Disease States
2016 •
Elena Fernandez
Higher medication adherence is associated with positive health outcomes, including reduction in hospitalizations and costs, and many interventions have been implemented to increase patient adherence. To determine whether patients experience higher medication adherence by using mail-order or retail pharmacies. Articles pertaining to retail and mail-order pharmacies and medication adherence were collected from 3 literature databases: MEDLINE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and International Pharmaceutical Abstracts (IPA). Searches were created for each database and articles were compiled. Articles were screened for exclusion factors, and final articles (n=15) comparing medication adherence in patients utilizing mail and retail pharmacies were analyzed. For each study, various factors were identified including days supply, patients' out-of-pocket costs, prior adherence behavior, therapeutic class, measure of adherence, limitations, and results. S...
230 Factors Associated With Initiation With Atomoxetine Versus Stimulants in the Treatment of Adults With ADHD: Retrospective Analysis of Administrative Claims Data
2006 •
David L Van Brunt
OBJECTIVE: To determine which factors are associated with use of atomoxetine (ATX) relative to stimulant medications (STIMs) for treatment initiation in adults with attention-deficit/hyperactivity disorder (ADHD). A similar exploratory analysis of the use of ATX versus STIMs in children has been published previously. METHODS: This was an exploratory analysis using a retrospective observational cohort design applied to administrative pharmacy and
Journal of medical economics
Treatment patterns among patients with psoriasis using a large national payer database in the United States: a retrospective study
2018 •
Kalyani Sonawane
Characterize treatment patterns of psoriasis patients in a large U.S. managed care database. Adults with newly diagnosed psoriasis were identified from 07/03/2006-08/31/2014. Patients had continuous enrollment with medical and pharmacy benefits for ≥6 months prior to and ≥1 year following the index date. Index date was the point at which any of the following inclusion criteria were satisfied: first psoriasis diagnosis by a dermatologist, ≥2 psoriasis diagnoses ≥30 days apart, or a diagnosis of psoriasis followed by a claim for psoriasis therapy. Of primary interest was to measure and describe the following psoriasis treatment patterns: utilization rates, time to treatment discontinuation, and lines of therapy for various therapeutic classes of pharmacologic therapies. From the 128,308 patients identified, 53% were female, mean ± SD age was 50 ± 16 years, with median 3 years follow-up. Topicals were received by 86% of patients, non-biologic systemics by 13%, biologics by 6%, photothe...
Journal of managed care & specialty pharmacy
Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid
2018 •
David Thompson
Outcomes involving newer direct-acting antiviral (DAA) hepatitis C virus (HCV) regimens have not been studied extensively among the Medicaid population. To assess clinical (treatment failure) and economic outcomes for chronic HCV-infected Oklahoma Medicaid members following treatment with DAAs and to measure associations with patient, treatment, and clinical characteristics. This cross-sectional study used Oklahoma Medicaid pharmacy and medical claims data for adult members who used a newer DAA agent and had reported a successful or failed sustained virological response rate 12 weeks after therapy completion (SVR12) from January 1, 2014, to June 30, 2016. Multivariable logistic and gamma regressions assessed predictors of SVR12 failure and costs controlling for member demographics (i.e., age, sex, race, rural residence); type of DAA and adherence; clinical characteristics (e.g., comorbid conditions, advanced liver disease); and the implementation of changes to a prior authorization ...
